Ovarian and adrenal hyperandrogenism

Annals of the New York Academy of Sciences

Volumn 1092, Issue , 2006, Pages 130-137

  Carmina, Enrico ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Androgen excess; Idiopathic hyperandrogenism; NCAH; Nonclassic 21 hydroxylase deficiency; PCOS; Polycystic ovary syndrome

Indexed keywords

HYDROCORTISONE; INSULIN; PRASTERONE SULFATE; STEROID; STEROID 21 MONOOXYGENASE;

ANDROGEN RELEASE; BODY WEIGHT; CONFERENCE PAPER; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; PHENOTYPE; STEROID 21 MONOOXYGENASE DEFICIENCY; STEROID METABOLISM; ADRENAL GLAND; FEMALE; OVARY; PATHOPHYSIOLOGY; REVIEW; SECRETION;

ADRENAL GLANDS; FEMALE; HUMANS; HYPERANDROGENISM; OVARY; POLYCYSTIC OVARY SYNDROME; STEROID 21-HYDROXYLASE;

EID: 34247189025     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1365.011     Document Type: Conference Paper

References (43)

1. CARMINA, E. & R.A. LOBO. 1999. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J. Clin. Endocrinol. Metab. 84: 1897-1899.
2. KNOCHENHAUER, E.S., T.J. KEY, W. KAHSAR- MILLER, et al. 1998. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern USA: a prospective study. J. Clin. Endocrinol. Metab. 83: 3078-3082.
3. DIAMANTI-KANDARAKIS, E., C.R. KOULI, A.T. BERGIELE, et al. 1999. A survey of polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84: 4006-4011.
4. CARMINA, E. 2006. Mild androgen disorders. Best Pract. Res. Clin. Endocrinol. Metab. 20: 207-220.
5. MAROULIS, G.B. 1981. Evaluation of hirsutism and hyperandrogenemia. Fertil. Steril. 36: 273-305.
6. AZZIZ, R., L.A. SANCHEZ, E.S. KNOCHENHAUER, et al. 2004. Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab. 89: 453-462.
7. CARMINA, E., F. ROSATO, A. JANNÌ, et al. 2005. Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J. Clin. Endocrinol. Metab. 91: 2-6.
8. BARNES, R.B., R.L. ROSENFIELD, S. BURNSTEIN & D.A. EHRMANN. 1989. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N. Engl. J. Med. 320: 559-565.
9. ESCOBAR-MORREALE, H.F., M. LUQUE-RAMIREZ & J.L. SAN MILLAN. 2005. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr. Rev. 26: 251-282.
10. ABBOTT, D.H., D.K. BARNETT, C.M. BRUNS & D.A. DUMESIC. 2005. Androgen excess fetal programming of female reproduction: a developmental etiology for polycystic ovary syndrome? Hum. Reprod. Update 11: 357-374.
11. GILLING-SMITH, C., D.S. WILLIS, R.W. BEARD & S. FRANKS. 1994. Hypersecretion of androstenedione by isolated theca cells from polycystic ovaries. J. Clin. Endocrinol. Metab. 79: 1158-1165.
12. GILLING-SMITH, C., H. STORY, V. ROGERS & S. FRANKS. 1997. Evidence for a primary abnormality of theca cell steroidogenesis in the polycystic ovary syndrome. Clin. Endocrinol. (Oxf) 47: 93-99.
13. CARMINA, E. 1997. Prevalence of adrenal androgen excess in PCOS. In Androgen Excess Disorders in Women. R.A. Azziz, J.B. Nestler & D. Dewailly, Eds.: 385-393. Lippincott-Raven. Philadelphia, PA.
14. CARMINA, E., F. ROSATO & A. JANNÌ. 1986. Increased DHEAS levels in PCO syndrome: evidence for the existence of two subgroups of patients. J. Endocrinol. Invest. 9: 5-10.
15. STANCZYK, F.Z., L. CHANG, E. CARMINA, et al. 1991. Is 11β-hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate? Am. J. Obstet. Gynecol. 165: 1837-1842.
16. KUMAR, A., K.S. WOODS, A.A. BARTOLUCCI & R. AZZIZ. 2005. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin. Endocrinol. (Oxf) 62: 644-649.
17. CARMINA, E. & R.A. LOBO. Prevalence and characteristics of adrenal androgen secretion in patients with different forms of androgen excess disorders. Hum. Reprod. In press.
18. ROTTERDAM ESHRE/ASRM SPONSORED PCOS CONSENSUS WORKSHOP GROUP. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81: 19-25.
19. ROTTERDAM ESHRE/ASRM SPONSORED PCOS CONSENSUS WORKSHOP GROUP. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum. Reprod. 19: 41-47.
20. LEGRO, R.S., A.R. KUNSELMAN, L. DEMERS, et al. 2002. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87: 2134-2138.
21. AZZIZ, R.A. 1997. Abnormalities of adrenocortical steroidogenesis in PCOS. In Androgen Excess Disorders in Women. R.A. Azziz, J.B. Nestler & D. Dewailly, Eds.: 403-414. Lippincott-Raven. Philadelphia, PA.
22. CARMINA, E. & R.A. LOBO. 1990. Pituitary-adrenal responses to ovine corticotropin-releasing hormone in polycystic ovary syndrome and in other hyperandrogenic patients. Gynecol. Endocrinol. 4: 225-232.
23. AZZIZ, R., V. BLACK, G.A. HINES, et al. 1998. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J. Clin. Endocrinol. Metab. 83: 2317-2323.
24. MORAN, C., R. REYNA, L.S. BOOTS & R.A. AZZIZ. 2004. Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess. Fertil. Steril. 81: 126-131.
25. CARMINA, E. 1997. The role of extra-adrenal factors in adrenal androgen excess: in vivo studies. In Androgen Excess Disorders in Women. R.A. Azziz, J.B. Nestler & D. Dewailly, Eds.: 425-434. Lippincott-Raven. Philadelphia, PA.
26. MOGHETTI, P., R. CASTELLO, C. NEGRI, et al. 1996. Insulin infusion amplifies 17a-hydroxyxorticosteroid intermediate response to adrenocorticotropin in hyperandrogenic women. Apparent relative impairment of 17,20 lyase activity. J. Clin. Endocrinol. Metab. 81: 881-886.
27. MORAN, C., E. KNOCHENHAUER, L.R. BOOTS & R.A. AZZIZ. 1999. Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertil. Steril. 71: 671-674.
28. CARMINA, E., F. GONZALEZ, A. VIDALI, et al. 1999. The contribution of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome. Hum. Reprod. 14: 307-311.
29. DITKOFF, E.C., F. FRUZZETTI, L. CHANG, et al. 1995. The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80: 603-607.
30. WALKER, B.R., A. RODIN, N.F. TAYLOR & R.N. CLAYTON. 2000. Endogenous inhibitors of 11beta-hydroxysteroid dehydrogenase type I do not explain abnormal cortisol metabolism in polycystic ovary syndrome. Clin. Endocrinol. (Oxf) 52: 77-80.
31. TSILCHOROZIDOU, T., J.W. HONOUR & G.S. CONWAY. 2003. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. J. Clin. Endocrinol. Metab. 88: 5907-5913.
32. LOBO, R.A. & U. GOEBELSMANN. 1981. Evidence for reduced 3β-ol-hydroxysteroid dehydrogenase activity in some hirsute women thought to have polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 53: 394-400.
33. ZERAH, M., E. RHEAUME, P. MANI, et al. 1994. No evidence of mutations in the genes for type I and type II 3β-hydroxysteroid dehydrogenase (3β-HSD) in nonclassical 3β-HSD deficiency. J. Clin. Endocrinol. Metab. 79: 1811-1817.
34. CARBUNARU, G., P. PRASAD, B. SCOCCIA, et al. 2004. The hormonal phenotype of nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency. J. Clin. Endocrinol. Metab. 89: 783-794.
35. STEINBERGER, E., K.D. SMITH & L.J. RODRIGUEZ-RIGAU. 1984. Testosterone, dehydroepiandrosterone, and dehydroepiandrosterone sulfate in hyperandrogenic women. J. Clin. Endocrinol. Metab. 59: 471-477.
36. NEW, M.I. & P.W. SPEISER. 1986. Genetics of adrenal steroid 21-hydroxylase deficiency. Endocr. Rev. 7: 331-349.
37. AZZIZ, R., D. DEWAILLY & D. OWERBACH. 1994. Nonclassic adrenal hyperplasia: current concepts. J. Clin. Endocrinol. Metab. 78: 810-815.
38. CARMINA, E., F.Z. STANCZYK, L. CHANG, et al. 1992. The ratio of androstenedione: 11b-hydroxyandrostenedione is an important marker of adrenal androgen excess in women. Fertil. Steril. 58: 148-152.
39. LOBO, R.A. & U. GOEBELSMANN. 1980. Adult manifestations of congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency mimicking polycystic ovarian disease. Am. J. Obstet. Gynecol. 138: 720-726.
40. CARMINA, E., A.M. GAGLIANO, F. ROSATO, et al. 1984. The endocrine pattern of late onset adrenal hyperplasia (21-hydroxylase deficiency). J. Endocrinol. Invest. 7: 89-92.
41. DEWAILLY, D., M.C. VANTYGHEM-HAUDIQUET, C. SAINSARD, et al. 1986. Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 63: 418-423.
42. CARMINA, E. & R.A. LOBO. 1994. Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Fertil. Steril. 62: 738-743.
43. LEVIN, J.H., E. CARMINA & R.A. LOBO. 1991. Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia? Fertil. Steril. 56: 635-640.